p.80 抽出テキスト
CLINICAL STATEMENTS AND GUIDELINES Circulation. 2025;152:e114–e218. DOI: 10.1161/CIR.0000000000001356 September 16, 2025 e193 5 Turcu AF, Yang J, Vaidya A. Primary aldosteronism: a multidimensional syn drome. Nat Rev Endocrinol. 2022;18:665–682. 6. Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hyperten sion: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41–50. 7. Monticone S, Sconfienza E, D'Ascenzo F, et al. Renal damage in prima ry aldosteronism: a systematic review and meta-analysis. J Hypertens. 2020;38:3–12. 8. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045–1050. 9. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–2300. 10. Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifesta tions of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811–1820. 11. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies-a review of the current literature. Horm Metab Res. 2012;44:157–162. 12. Hundemer GL, Curhan GC, Yozamp N, et al. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72:658– 666. 13. Hundemer GL, Curhan GC, Yozamp N, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51–59. 14. Cohen JB, Cohen DL, Herman DS, et al. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among US veterans: a retro spective cohort study. Ann Intern Med. 2021;174:289–297. 15. Hundemer GL, Imsirovic H, Vaidya A, et al. Screening rates for primary aldoste ronism among individuals with hypertension plus hypokalemia: a populationbased retrospective cohort study. Hypertension. 2022;79:178–186. 16. Kim V, Shi J, An J, et al. Hyperaldosteronism screening and findings from a large diverse population with resistant hypertension within an integrated health system. Perm J. 2024;28:3–13. 17. Kositanurit W, Giacona JM, Xie D, et al. Trends in primary aldosteron ism screening among high-risk hypertensive adults. J Am Heart Assoc. 2024;13:e036373. 18. Woode ME, Wong K, Reid CM, et al. Cost-effectiveness of screening for primary aldosteronism in hypertensive patients in Australia: a Markov model ling analysis. J Hypertens. 2023;41:1615–1625. 19. Sato M, Morimoto R, Seiji K, et al. Cost-effectiveness analysis of the diag nosis and treatment of primary aldosteronism in Japan. Horm Metab Res. 2015;47:826–832. 20. Montori VM, Young WF Jr. Use of plasma aldosterone concentration-toplasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am. 2002;31:619–632. 21. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma re nin activity ratio in primary aldosteronism. Hypertension. 2002;40:897–902. 22. Samnani S, Cenzer I, Kline GA, et al. Time to benefit of surgery vs targeted medical therapy for patients with primary aldosteronism: a meta-analysis. J Clin Endocrinol Metab. 2024;109:e1280-e1289. 23. Griffin AC, Kelz R, LiVolsi VA. Aldosterone-secreting adrenal corti cal carcinoma. A case report and review of the literature. Endocr Pathol. 2014;25:344–349. 3.2.3.2 Renal Artery Stenosis 1 Riaz IB, Husnain M, Riaz H, et al. Meta-analysis of revascularization ver sus medical therapy for atherosclerotic renal artery stenosis. Am J Cardiol. 2014;114:1116–1123. 2. Jenks S, Yeoh SE, Conway BR. Balloon angioplasty, with and without stent ing, versus medical therapy for hypertensive patients with renal artery ste nosis. Cochrane Database Syst Rev 2014;2014:CD002944. 3. Raman G, Adam GP, Halladay CW, et al. Comparative effectiveness of man agement strategies for renal artery stenosis: an updated systematic review. Ann Intern Med. 2016;165:635–649. 4. Trinquart L, Mounier-Vehier C, Sapoval M, et al. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension. 2010;56:525–532. 5. Olin JW, Froehlich J, Gu X, et al. The United States registry for fibromuscu lar dysplasia: results in the first 447 patients. Circulation. 2012;125:3182– 3190. 6 Bhalla V, Textor SC, Beckman JA, et al. Revascularization for renovascular disease: a scientific statement from the American Heart Association. Hyper tension. 2022;79:e128-e143. 7. Murphy TP, Cooper CJ, Pencina KM, et al. Relationship of albuminuria and renal artery stent outcomes: results from the CORAL randomized clinical trial (Cardiovascular Outcomes with Renal Artery Lesions). Hypertension. 2016;68:1145–1152. 8. Misra S, Khosla A, Allred J, et al. Mortality and renal replacement therapy after renal artery stent placement for atherosclerotic renovascular disease. J Vasc Interv Radiol. 2016;27:1215–1224. 9. Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13–22. 3.2.3.3 Obstructive Sleep Apnea 1 Kovacs DK, Gede N, Szabo L, et al. Weight reduction added to CPAP de creases blood pressure and triglyceride level in OSA: systematic review and meta-analysis. Clin Transl Sci. 2022;15:1238–1248. 2. Labarca G, Schmidt A, Dreyse J, et al. Efficacy of continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA) and resis tant hypertension (RH): systematic review and meta-analysis. Sleep Med Rev. 2021;58:101446. 3. Lei Q, Lv Y, Li K, et al. Effects of continuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a systematic review and meta-analysis of six randomized controlled trials. J Bras Pneumol. 2017;43:373–379. 4. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for di agnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13:479– 504. 5. Hou H, Zhao Y, Yu W, et al. Association of obstructive sleep apnea with hypertension: a systematic review and meta-analysis. J Glob Health. 2018;8:010405. 6. Marshall NS, Wong KK, Cullen SR, et al. Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton Health Study cohort. J Clin Sleep Med. 2014;10:355–362. 7. Kou C, Zhao X, Lin X, et al. Effect of different treatments for obstructive sleep apnoea on blood pressure. J Hypertens. 2022;40:1071–1084. 8. Patil SP, Ayappa IA, Caples SM, et al. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medi cine clinical practice guideline. J Clin Sleep Med. 2019;15:335–343. 9. McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovas cular events in obstructive sleep apnea. N Engl J Med. 2016;375:919– 931. 10. Kang KT, Yeh TH, Ko JY, et al. Effect of sleep surgery on blood pressure in adults with obstructive sleep apnea: a systematic review and meta-analysis. Sleep Med Rev. 2022;62:101590. 11. Schwartz AR, Jacobowitz O, Eisele DW, et al. Targeted hypoglossal nerve stimulation for patients with obstructive sleep apnea: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2023;149:512–520. 12. Stelmach-Mardas M, Brajer-Luftmann B, Kusnierczak M, et al. Body mass index reduction and selected cardiometabolic risk factors in obstructive sleep apnea: meta-analysis. J Clin Med. 2021;10:1485. 13. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391:1193–1205. 14. Ahmed AM, Nur SM, Xiaochen Y. Association between obstructive sleep ap nea and resistant hypertension: systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1200952. 15. Brown J, Yazdi F, Jodari-Karimi M, et al. Obstructive sleep apnea and hypertension: updates to a critical relationship. Curr Hypertens Rep. 2022;24:173–184. 16. Navarro-Soriano C, Torres G, Barbe F, et al. The HIPARCO-2 study: long- term effect of continuous positive airway pressure on blood pressure in patients with resistant hypertension: a multicenter prospective study. J Hy pertens. 2021;39:302–309. 4 Prevention Strategies 1. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a Presidential Advisory from the American Heart As sociation. Circulation. 2022;146:e18-e43. 2. Di Federico S, Filippini T, Whelton PK, et al. Alcohol intake and blood pres sure levels: a dose-response meta-analysis of nonexperimental cohort stud ies. Hypertension. 2023;80:1961–1969. Downloaded from http://ahajournals.org by on October 7, 2026